NTRK fusion in GIST is rare and confined to KIT/PDGFRA wild-type GIST (which is itself ~1...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-NTRK-FUSION-GIST |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-GIST |
| Sources | SRC-FDA-CDS-2026 |
Actionability Facts
| Biomarker | BIO-NTRK-FUSION |
|---|---|
| Variant | NTRK1/3 fusion (rare in KIT/PDGFRA wild-type GIST) |
| Disease | DIS-GIST |
| ESCAT tier | IA |
| Recommended combinations | larotrectinib monotherapy, entrectinib monotherapy |
| Contraindicated monotherapy | imatinib (KIT/PDGFRA-WT GIST is imatinib-refractory) |
| Evidence summary | NTRK fusion in GIST is rare and confined to KIT/PDGFRA wild-type GIST (which is itself ~10-15% of GIST). Larotrectinib and entrectinib are FDA tumor-agnostic for NTRK-fusion solid tumors; GIST cohort small but consistent with pan-tumor response rates. |
Notes
ESCAT IA. OncoKB Level 1. NTRK-fusion screening in GIST should be reserved for KIT/PDGFRA-WT cases (after SDHB IHC to exclude SDH-deficient GIST). Source-gap: SRC-NCCN-SARCOMA / SRC-NCCN-GIST-2025 not yet ingested.
Used By
No reverse references found in the YAML corpus.